Sartorius AG reported group sales revenue increased by 7.7% on an operational basis in constant currencies for the first half of 2026. The Bioprocess Solutions division grew 8.3% operationally, driven by consumables, while Lab Products and Services rose 5.3%. Underlying EBITDA margin improved to 30.3%, and free cash flow jumped more than 70% to 208 million euros. Net debt to underlying EBITDA improved to 3.51 times from 3.55 times at year-end 2025, and underlying net profit increased 2% to 172 million euros. The company noted tariff-related customer compensations created a temporary headwind, and delayed orders from two major customers in advanced therapies impacted recurring revenue growth.
Sartorius AktiengesellschaftSartorius AG reported 7.7% revenue growth, 30.3% EBITDA margin, and 70% free cash flow surge, indicating strong financial performance.
Sartorius Stedim Biotech SASartorius Stedim Biotech is the bioprocess subsidiary; the parent's strong earnings and cash flow growth reflect positively on its performance.